DormoVision X Launches at SLEEP 2025

Revolutionizing sleep health with an all-in-one, AI-driven diagnostics platform. Delivering real-time physiological data monitoring and sleep analysis that matches the accuracy and quality of in-lab studies, with the comfort and convenience of at-home testing.

Dormotech, a leader in advancing sleep diagnostics through innovative, clinically validated solutions, is proud to launch DormoVision X™ at SLEEP 2025, Booth #1019. This FDA-cleared, wireless home sleep testing device delivers real time data and diagnostic accuracy comparable to gold-standard polysomnography (PSG), with 96.6% equivalence, reshaping how sleep labs deliver care and scale their clinics.

With millions affected by sleep disorders like obstructive sleep apnea (OSA), traditional in-lab PSG can be costly, inconvenient, and resource-intensive. Meanwhile, many home testing options are limited and fall short in capturing comprehensive sleep data. DormoVision X™ addresses this gap with a patient-centric, wireless design—validated in a 2025 Sleep and Breathing study to deliver 96.6% agreement with PSG across AHI, sleep stages, EEG, EOG, EMG, and oxygen saturation (Cohen’s Kappa 0.97). Rated 4+/5 for comfort and ease, with zero reported adverse events, DormoVision X™ enables natural sleep at home while providing clinicians with real time data insights and lab-quality diagnostics.

“As a pediatric sleep specialist, I’ve always looked for more accurate readings for children. DormoVision’s home testing capability has been revolutionary—children sleep in their own beds, and I receive clinical-grade data across all 25 signals. It’s a game changer,” said Prof. Asher Tal, MD, Professor Emeritus of Pediatrics and Founder of the Pediatric Pulmonary Unit and Sleep Laboratory at Soroka Medical Center, Ben-Gurion University.

DormoVision X™ portable, multi-night testing capability reduces turnaround times and scheduling bottlenecks, allowing labs to serve more patients in a single night without the high upfront costs of in-lab equipment. This not only drives significant operational savings but also aligns with Dormotech’s mission to advance early disease detection and treatment through precise, accessible sleep data.

“DormoVision X™ redefines sleep diagnostics by bringing lab accuracy to patients’ homes, making early OSA detection more accessible and cost-effective than ever,” said Abed Nassir, CEO of Dormotech. “We’re excited to launch at SLEEP 2025, where labs can see how our technology transforms patient care.”

Source: Dormotech